Amgen's rare disease drug tied to deaths and liver injuries in Japan, reports WSJ

• 20 deaths reported among Japanese patients who took the Amgen rare disease drug
• 22 additional patients developed potentially fatal liver injuries linked to the medication
• Information was disclosed by Amgen's partner company Kissei Pharmaceutical in Japan

Summary: Amgen's Rare Disease Drug Linked to Deaths and Liver Injuries in Japan

Amgen's rare disease drug has been associated with at least 20 deaths in Japan, according to a Wall Street Journal report citing the company's partner Kissei Pharmaceutical. Additionally, 22 patients developed potentially fatal liver injuries while taking the medication.

Key Facts:

• Deaths reported: At least 20 fatalities in Japan
• Severe adverse events: 22 cases of potentially fatal liver injuries
• Source: Information disclosed by Kissei Pharmaceutical, Amgen's Japanese partner
• Date: Report published May 15

Companies Involved:

• Amgen (AMGN): Major U.S. biotechnology company facing serious safety concerns with its rare disease treatment
• Kissei Pharmaceutical: Amgen's Japanese partner responsible for reporting the adverse events

Market Implications:

This development poses significant regulatory and reputational risks for Amgen. Safety issues of this magnitude typically trigger:

• Potential regulatory investigations by Japanese health authorities
• Possible drug recalls or label warnings
• Risk of similar scrutiny in other markets where the drug is approved
• Potential liability exposure and legal challenges
• Negative impact on Amgen's stock price and investor confidence

The severity of the adverse events—including deaths and life-threatening liver injuries—may result in restricted use, additional safety requirements, or withdrawal of the drug from the Japanese market. This incident could also affect Amgen's broader rare disease portfolio and partnerships.

The article did not specify which rare disease drug was involved, leaving uncertainty about the financial impact on Amgen's revenue streams. Investors should monitor for additional disclosures from Amgen and regulatory actions.